Who Pays, Who Benefits? Producer-Insurer Games in Life-Saving Medicines
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015.
"Pricing in the Market for Anticancer Drugs,"
Journal of Economic Perspectives, American Economic Association, vol. 29(1), pages 139-162, Winter.
- David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," NBER Working Papers 20867, National Bureau of Economic Research, Inc.
- Mark Duggan & Fiona Scott Morton, 2010.
"The Effect of Medicare Part D on Pharmaceutical Prices and Utilization,"
American Economic Review, American Economic Association, vol. 100(1), pages 590-607, March.
- Mark Duggan & Fiona Scott Morton, 2008. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," NBER Working Papers 13917, National Bureau of Economic Research, Inc.
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Joseph S. Pliskin & Donald S. Shepard & Milton C. Weinstein, 1980. "Utility Functions for Life Years and Health Status," Operations Research, INFORMS, vol. 28(1), pages 206-224, February.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Liran Einav & Amy Finkelstein & Maria Polyakova, 2018.
"Private Provision of Social Insurance: Drug-Specific Price Elasticities and Cost Sharing in Medicare Part D,"
American Economic Journal: Economic Policy, American Economic Association, vol. 10(3), pages 122-153, August.
- Liran Einav & Amy Finkelstein & Maria Polyakova, 2016. "Private Provision of Social Insurance: Drug-specific Price Elasticities and Cost Sharing in Medicare Part D," NBER Working Papers 22277, National Bureau of Economic Research, Inc.
- Martin Gaynor & Kate Ho & Robert J. Town, 2015.
"The Industrial Organization of Health-Care Markets,"
Journal of Economic Literature, American Economic Association, vol. 53(2), pages 235-284, June.
- Martin Gaynor & Kate Ho & Robert Town, 2014. "The Industrial Organization of Health Care Markets," NBER Working Papers 19800, National Bureau of Economic Research, Inc.
- Benjamin R. Handel & Kate Ho, 2021. "Industrial Organization of Health Care Markets," NBER Working Papers 29137, National Bureau of Economic Research, Inc.
- Besanko, David & Dranove, David & Garthwaite, Craig, 2020. "Insurance access and demand response: Pricing and welfare implications," Journal of Health Economics, Elsevier, vol. 73(C).
- Lakdawalla, Darius & Sood, Neeraj, 2009. "Innovation and the welfare effects of public drug insurance," Journal of Public Economics, Elsevier, vol. 93(3-4), pages 541-548, April.
- Jena, Anupam B. & Philipson, Tomas J., 2013.
"Endogenous cost-effectiveness analysis and health care technology adoption,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
- Anupam Jena & Tomas Philipson, 2009. "Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption," NBER Working Papers 15032, National Bureau of Economic Research, Inc.
- Kevin M. Murphy & Robert H. Topel, 2006.
"The Value of Health and Longevity,"
Journal of Political Economy, University of Chicago Press, vol. 114(5), pages 871-904, October.
- Kevin M. Murphy & Robert H. Topel, 2005. "The Value of Health and Longevity," NBER Working Papers 11405, National Bureau of Economic Research, Inc.
- Matthew Grennan, 2013. "Price Discrimination and Bargaining: Empirical Evidence from Medical Devices," American Economic Review, American Economic Association, vol. 103(1), pages 145-177, February.
- Nyman, John A., 1999. "The value of health insurance: the access motive," Journal of Health Economics, Elsevier, vol. 18(2), pages 141-152, April.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Kamphorst, Jurjen & Karamychev, Vladimir A., 2025.
"Going through the roof: On prices for drugs sold through insurance,"
Games and Economic Behavior, Elsevier, vol. 151(C), pages 218-242.
- Jurjen Kamphorst & Vladimir Karamychev, 2021. "Going Through The Roof: On Prices for Drugs Sold Through Insurance," Tinbergen Institute Discussion Papers 21-005/VII, Tinbergen Institute.
- Kortelainen, Mika & Markkanen, Jaakko & Toivanen, Otto & Siikanen, Markku, 2023.
"The Effects of Price Regulation on Pharmaceutical Expenditure and Availability,"
CEPR Discussion Papers
18497, C.E.P.R. Discussion Papers.
- Kortelainen, Mika & Markkanen, Jaakko & Siikanen, Markku & Toivanen, Otto, 2023. "The Effects of Price Regulation on Pharmaceutical Expenditure and Availability," Working Papers 157, VATT Institute for Economic Research.
- Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2021.
"R&D-driven medical progress, health care costs, and the future of human longevity,"
The Journal of the Economics of Ageing, Elsevier, vol. 18(C).
- Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2017. "R&D-driven medical progess, health care costs, and the future of human longevity," University of Göttingen Working Papers in Economics 325, University of Goettingen, Department of Economics.
- Sebastian Böhm & Volker Grossmann & Holger Strulik, 2018. "R&D-Driven Medical Progress, Health Care Costs, and the Future of Human Longevity," CESifo Working Paper Series 6897, CESifo.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Pierre Dubois & Morten Sæthre, 2020.
"On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector,"
Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
- Dubois, Pierre & Sæthre, Morten, 2017. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Discussion Paper Series in Economics 3/2018, Norwegian School of Economics, Department of Economics.
- Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Post-Print hal-03176406, HAL.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," TSE Working Papers 18-883, Toulouse School of Economics (TSE), revised Mar 2020.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
- Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.
- Leila Agha & Soomi Kim & Danielle Li, 2022.
"Insurance Design and Pharmaceutical Innovation,"
American Economic Review: Insights, American Economic Association, vol. 4(2), pages 191-208, June.
- Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
- Boone, Jan, 2020.
"Pricing above Value: Selling to an Adverse Selection Market,"
Discussion Paper
2020-023, Tilburg University, Center for Economic Research.
- Boone, Jan, 2020. "Pricing above Value: Selling to an Adverse Selection Market," Discussion Paper 2020-023, Tilburg University, Tilburg Law and Economic Center.
- Boone, Jan, 2020. "Pricing above Value: Selling to an Adverse Selection Market," Other publications TiSEM 700b2f3e-d1c8-4422-9b54-f, Tilburg University, School of Economics and Management.
- Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
- Boone, Jan, 2013.
"Does the market choose optimal health insurance coverage?,"
CEPR Discussion Papers
9420, C.E.P.R. Discussion Papers.
- Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Discussion Paper 2013-008, Tilburg University, Tilburg Law and Economic Center.
- Dubois, Pierre, 2025.
"Pharmaceutical Regulation and Incentives for Innovation in an International Perspective,"
TSE Working Papers
25-1674, Toulouse School of Economics (TSE).
- Pierre Dubois, 2025. "Pharmaceutical Regulation and Incentives for Innovation in an International Perspective," Working Papers hal-05310888, HAL.
- Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Other publications TiSEM f7691fbf-f770-4714-b1b4-1, Tilburg University, School of Economics and Management.
- Amitabh Chandra & Jonathan Skinner, 2012.
"Technology Growth and Expenditure Growth in Health Care,"
Journal of Economic Literature, American Economic Association, vol. 50(3), pages 645-680, September.
- Amitabh Chandra & Jonathan S. Skinner, 2011. "Technology Growth and Expenditure Growth in Health Care," NBER Working Papers 16953, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
Research Papers
3889, Stanford University, Graduate School of Business.
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," NBER Working Papers 30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
- David Besanko & David Dranove & Craig Garthwaite, 2016. "Insurance and the High Prices of Pharmaceuticals," NBER Working Papers 22353, National Bureau of Economic Research, Inc.
- David B. Ridley & Chung-Ying Lee, 2020. "Does Medicare Reimbursement Drive Up Drug Launch Prices?," The Review of Economics and Statistics, MIT Press, vol. 102(5), pages 980-993, December.
- Branstetter, Lee G. & Kwon, Namho, 2018. "South Korea's transition from imitator to innovator: The role of external demand shocks," Journal of the Japanese and International Economies, Elsevier, vol. 49(C), pages 28-42.
- Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
More about this item
NEP fields
This paper has been announced in the following NEP Reports:- NEP-COM-2025-10-20 (Industrial Competition)
- NEP-GTH-2025-10-20 (Game Theory)
- NEP-HEA-2025-10-20 (Health Economics)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:arx:papers:2509.16125. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: arXiv administrators (email available below). General contact details of provider: http://arxiv.org/ .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.
Printed from https://ideas.repec.org/p/arx/papers/2509.16125.html